ITRMF (Iterum Therapeutics) Tariff Resilience Score: 5/10 (As of Jun. 26, 2026)


What is Iterum Therapeutics Tariff Resilience Score?

Iterum Therapeutics ITRMF +18.86% Tariff Resilience Score is 5 as of Jun. 26, 2026. The stock has 4 warning signs investors should review. Among 1,379 Biotechnology companies, Iterum Therapeutics ranks better than 62.22% on this metric.

Iterum Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Iterum Therapeutics has ITRM's pharmaceutical focus means limited direct tariff exposure, but supply chain dependencies on imported ingredients and equipment pose risks. Regulatory exemptions may mitigate some impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Iterum Therapeutics might have Average Resilient.

Iterum Therapeutics  (OTCPK:ITRMF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Iterum Therapeutics Tariff Resilience Score Related Terms

ITRMF vs ENSC, PPCB, REVB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Iterum Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Iterum Therapeutics (ITRMF) has a Tariff Resilience Score of 5 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Iterum Therapeutics ranks #521 out of 1379 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Iterum Therapeutics' Tariff Resilience Score too high?
Iterum Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Iterum Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Iterum Therapeutics ranks #521 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint.
How does Iterum Therapeutics' Tariff Resilience Score compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #521 out of 1379 companies for Tariff Resilience Score. This puts Iterum Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Iterum Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iterum Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Tariff Resilience Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.